ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1321

Inhibition of the Mechanistic Target of Rapamycin Pathway and Glutaminolysis Facilitates the Expansion of Myeloid-Derived Suppressor Cells and Synergistically Ameliorates Arthritis in SKG Mice

Yo Ueda1, Takaichi Okano1, Hirotaka Yamada1, Yoshihide Ichise1, Ikuko Naka2, Soshi Takahashi3, Sho Sendo4, Kengo Akashi2, Akira Onishi5, Jun Saegusa4 and Akio Morinobu3, 1Department of Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 2Kobe University Graduate School of Medicine, Kobe, Japan, 3Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 4Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 5Rheumaology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Arthritis, mTor and metabolism

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Animal Models Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature cells that increase in the pathological state such as tumor or inflammation and have the immunosuppressive ability. MDSCs have been reported to ameliorate arthritis in several mice models. The mechanistic target of rapamycin (mTOR) pathway and glutaminolysis are known to be activated in the differentiation from myeloid progenitors to mature myeloid cells such as dendritic cells, macrophages, or osteoclasts. The aim of this study is to evaluate the facilitative effects of the inhibition of mTOR pathway and glutaminolysis on MDSCs in a mouse model of rheumatoid arthritis.

Methods:  Bone marrow (BM) cells from untreated Balb/c mice were cultured for 5 days under granulocyte–macrophage colony-stimulating factor (GM-CSF) stimulation with four patterns of drugs; 1) DMSO (control), 2) rapamycin, 3) 6-Diazo-5-oxo-L-norleucine (DON; a glutamine analogue), or 4) the combination of rapamycin and DON. Cultured BM cells were analyzed by flow cytometry. Cultured MDSCs were isolated by manual MACS and analyzed their immunosuppressive characters by co-culture with CFSE-dyed CD4+ T cells. The four patterns of drugs described above were administered intraperitoneally to arthritic SKG mice induced by Zymosan A injection.

Results:  We found that DON administration (separately or in combination) significantly suppressed the differentiation from BM cells to dendritic cells in vitro. Most DON-treated BM cells showed the phenotype of MDSCs, large part of which were Ly6G+ cells (the phenotype of polymorphonuclear MDSCs; PMN-MDSCs). On the other hand, rapamycin administration (separately or in combination) significantly increased the TGF-b expression and the inhibitory capacity of Ly6G+ PMN-MDSCs. The combination of rapamycin and DON was the most effective to suppress arthritis in SKG mice among these four treatment patterns (see Fig 1).

Conclusion: The combination of rapamycin and DON facilitates the expansion of PMN-MDSCs in vitro and synergistically ameliorates arthritis in SKG mice in vivo.


Disclosure: Y. Ueda, None; T. Okano, None; H. Yamada, None; Y. Ichise, None; I. Naka, None; S. Takahashi, None; S. Sendo, None; K. Akashi, None; A. Onishi, None; J. Saegusa, None; A. Morinobu, None.

To cite this abstract in AMA style:

Ueda Y, Okano T, Yamada H, Ichise Y, Naka I, Takahashi S, Sendo S, Akashi K, Onishi A, Saegusa J, Morinobu A. Inhibition of the Mechanistic Target of Rapamycin Pathway and Glutaminolysis Facilitates the Expansion of Myeloid-Derived Suppressor Cells and Synergistically Ameliorates Arthritis in SKG Mice [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/inhibition-of-the-mechanistic-target-of-rapamycin-pathway-and-glutaminolysis-facilitates-the-expansion-of-myeloid-derived-suppressor-cells-and-synergistically-ameliorates-arthritis-in-skg-mice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inhibition-of-the-mechanistic-target-of-rapamycin-pathway-and-glutaminolysis-facilitates-the-expansion-of-myeloid-derived-suppressor-cells-and-synergistically-ameliorates-arthritis-in-skg-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology